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Abstract: Osteoblasts undergo differentiation in response to various factors, including growth factors
and steroids. Bone mass is diminished in androgen- and/or growth hormone (GH)-deficient patients.
However the functional relationship between androgen and GH, and their combined effects on
bone metabolism, remains unclear. Here we investigated the mutual effects of androgen and GH on
osteoblastic marker expression using mouse myoblastic C2C12 and osteoblast-like MC3T3-E1 cells.
Combined treatment with dihydrotestosterone (DHT) and GH enhanced BMP-2-induced expression
of Runx2, ALP, and osteocalcin mRNA, compared with the individual treatments in C2C12 cells.
Co-treatment with DHT and GH activated Smad1/5/8 phosphorylation, Id-1 transcription, and ALP
activity induced by BMP-2 in C2C12 cells but not in MC3T3-E1 cells. The insulin-like growth factor
(IGF-I) mRNA level was amplified by GH and BMP-2 treatment and was restored by co-treatment
with DHT in C2C12 cells. The mRNA level of the IGF-I receptor was not significantly altered by GH
or DHT, while it was increased by IGF-I. In addition, IGF-I treatment increased collagen-1 mRNA
expression, whereas blockage of endogenous IGF-I activity using an anti-IGF-I antibody failed to
suppress the effect of GH and DHT on BMP-2-induced Runx2 expression in C2C12 cells, suggesting
that endogenous IGF-I was not substantially involved in the underlying GH actions. On the other
hand, androgen receptor and GH receptor mRNA expression was suppressed by BMP-2 in both cell
lines, implying the existence of a feedback action. Collectively the results showed that the combined
effects of androgen and GH facilitated BMP-2-induced osteoblast differentiation at an early stage by
upregulating BMP receptor signaling.
Keywords: androgen; bone morphogenetic protein (BMP); dihydrotestosteone (DHT); growth
hormone (GH); osteoblasts
1. Introduction
Osteoblasts that have arisen from mesenchymal stem cell precursors undergo differentiation in
response to various endocrine and autocrine/paracrine factors, including bone morphogenetic proteins
(BMPs), growth hormone (GH), insulin-like growth factor-I (IGF-I), vitamin D, and steroids [1,2].
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Among these, bone loss in patients with hypogonadism or hypopituitarism is closely related to
decreases in sex steroids and growth hormone (GH). Estrogens are critical for the maintenance of bone
mass in women, while a decrease in the androgen level also causes bone loss in men. Testosterone
replacement is beneficial for the maintenance of bone mineral density (BMD) [3,4], in which both the
effects of the androgen and estrogen converted from the androgen are likely to be involved [5].
On the other hand, GH also plays a key role in bone development and bone metabolism. It has
been reported that bone mass is diminished in GH-deficient patients and that GH replacement is
effective to reverse the bone loss. It has been shown that deficiencies of testosterone and GH are
associated with low BMD and lead to an increase in fracture risk [6,7]. It has also been shown that
testosterone replacement therapy and GH replacement therapy improve BMD in hypogonadal and
GH-deficient male patients [8,9]. However the functional interaction of androgen and the GH/IGF-I
axis in osteoblast differentiation and bone formation remains to be elucidated. It is also not clear
whether androgen has an impact on bone metabolism via GH effects without IGF-I, through IGF-I
action without GH, or independently of GH and IGF-I activity.
The pluripotent mesenchymal precursor cell line C2C12, a subclone of a mouse myoblastic cell
line, and the osteoblast-like cell line MC3T3-E1 have been used as models to investigate the early and
developed stages of osteoblast differentiation, respectively. Treatment with TGF-β ligands has distinct
effects on differentiation of C2C12 cells, in which BMP ligands inhibit myoblast differentiation and
facilitate osteoblastic differentiation [10]. Exposure to BMP ligands causes mesoderm induction and
mesenchymal stem cell differentiation into chondrocytes and osteoblasts as well as differentiation
of osteoprogenitor cells into osteoblasts. BMPs are also known to have roles in the regulation of
embryological development and endocrine functions [11,12]. The biological functions of BMPs are
mediated through the Smad signaling pathway via specific combinations of the corresponding BMP
receptors. We previously reported mutual effects between BMP receptors and estrogen receptor (ER)
signaling in the processes of osteoblast differentiation at the early stage of C2C12 cells [13,14] and bone
mineralization at the later stage using MC3T3-E1 cells [15].
In the present study, we investigated the combined effects of androgen and GH on osteoblast
marker expression in different stages of osteoblastic differentiation using two cell lines, with a
focus on the interaction between BMP activity and pathways of the androgen receptor (AR) and
the GH/IGF-I axis.
2. Materials and Methods
2.1. Reagents and Supplies
Dulbecco’s Modified Eagle’s Medium (DMEM), Minimum Essential Medium (MEM)-α,
penicillin-streptomycin solution, and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich
Co., Ltd. (St. Louis, MO, USA). 5α-dihydrotestosterone (DHT), recombinant human somatotropin (GH),
and IGF-I were also obtained from Sigma-Aldrich Co., Ltd. (St. Louis, MO, USA). Recombinant human
BMP-2, anti-mouse IGF-I antibody, and normal goat IgG were purchased from R & D Systems Inc.
(Minneapolis, MN, USA).
2.2. Cell Culture and Morphological Examination
C2C12 and MC3T3-E1 cell lines were obtained from American Type Culture Collection (Manassas,
VA, USA). C2C12 cells and MC3T3-E1 cells were cultured in high-glucose DMEM and MEM-α,
respectively, at 37 ◦C under a humid atmosphere of 95% air/5% CO2. Each medium was supplemented
with 10% fetal calf serum (FCS) and penicillin-streptomycin solution. Changes in cell morphology
were serially monitored using an inverted microscope.
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2.3. RNA Extraction, RT-PCR, and Quantitative Real-Time PCR Analysis
To prepare total cellular RNA, cells were cultured in a 12-well plate (2 × 105 viable cells/well)
and treated with the indicated concentrations of BMP-2 in combination with DHT, GH, and IGF-I
in serum-free DMEM. After 48-h culture, the medium was removed and the total cellular RNA was
extracted using TRIzol® (Invitrogen Corp., Carlsbad, CA, USA), quantified by measuring absorbance
at 260 nm, and stored at −80 ◦C. The extracted RNA (1.0 µg) was subjected to a reverse transcription
(RT) reaction using the First-Strand cDNA synthesis system® (Invitrogen Corp.) with random hexamer
(2 ng/µL), reverse transcriptase (200 U), and deoxynucleotide triphosphate (2.5 mM) at 42 ◦C for
55 min and at 70 ◦C for 10 min. PCR primer pairs, custom-ordered from Invitrogen Corp., were
selected from different exons of the corresponding genes, with the primer pairs for osterix, alkaline
phosphatase (ALP), runt-related transcription factor 2 (Runx2), osteocalcin, type-1 collagen (collagen-1),
Id-1, GH receptor (GHR), IGF-I and IGF-I receptor (IGF-IR), and ribosomal protein L19 (RPL19) as
a house-keeping gene being used as reported previously [13–19]. Primer pairs for the AR were
2521–2543 and 2711–2734 from GenBank accession #NM_013476. For the quantification of mRNA
levels of target genes, real-time PCR was performed using the LightCycler® Nano Real-Time PCR
system (Roche Diagnostic Co., Tokyo, Japan) under optimized annealing conditions at 60–62 ◦C.
The relative expression of each mRNA was calculated by the ∆ threshold cycle (Ct) method, in which
∆Ct was the value obtained by subtracting the Ct value of RPL19 mRNA from the Ct value of the
target mRNA, and the amount of target mRNA relative to RPL19 mRNA was expressed as 2−(∆Ct).
The results were expressed as the ratio of target mRNA to RPL19 mRNA.
2.4. Western Immunoblot Analysis
C2C12 cells (1 × 105 viable cells/well) were precultured in 12-well plates in DMEM containing
10% FCS for 24 h. After preculture, the medium was replaced with fresh serum-free medium, and the
cells were treated with the indicated concentrations of DHT and GH for 48 h. Following stimulation
with BMP-2 for 60 min, the cells were solubilized in 100 µL RIPA lysis buffer (Upstate Biotechnology,
Inc., Lake Placid, NY, USA) containing 1 mM Na3VO4, 1 mM sodium fluoride, 2% sodium dodecyl
sulfate, and 4% β-mercaptoethanol. The cell lysates were then subjected to SDS-PAGE/immunoblotting
analysis using anti-phospho-Smad1/5/8 (pSmad1/5/8) and total-Smad1 (tSmad1) (Cell Signaling
Technology, Inc., Beverly, MA, USA). The relative integrated density of each protein band was
digitized and analyzed by the C-DiGit® Blot Scanner System (LI-COR Biosciences, Lincoln, NE, USA).
For evaluating pSmad1/5/8 levels, ratios of the signal intensities of pSmad/tSmad1 were calculated.
2.5. ALP Activity Assay
C2C12 and MC3T3-E1 cells were cultured in a 12-well plate (1 × 105 viable cells/well) and treated
with the indicated concentrations of BMP-2, DHT and GH. After 72-h culture, cells were washed with
PBS and lysed with Cell Culture Lysis Reagent (Toyobo, Osaka, Japan), and then cellular ALP activity
in the lystes was determined by the fluorometric assay for 4-nitrophenol (Wako Chemical Co., Osaka,
Japan), as we previously reported [15,19].
2.6. Statistical Analysis
Results are shown as means ± SEM of data from at least three separate experiments, each
performed with triplicate samples. Differences between groups were analyzed for statistical significance
using ANOVA with Fisher’s PLSD test or the unpaired t-test, when appropriate, to determine differences
(StatView 5.0 software, Abacus Concepts, Inc., Berkeley, CA, USA). p values < 0.05 were accepted as
statistically significant.
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3. Results
First the individual effects of androgen on BMP-2-induced osteoblast differentiation were
examined using C2C12 cells (Figure 1). Treatment with BMP-2 (100 ng/mL) for 48 h significantly
increased mRNA levels of osteoblast differentiation markers, including Runx2, ALP, osteocalcin, osterix
and collagen-1, in C2C12 cells. It has been reported that 10−7 M of DHT, within a range of 10−6 to
10−9 M, stably induces myogenic marker and myotube protein expression in C2C12 cells [20–22].
Based on our pilot study using 10−8 to 10−6 M of DHT, a pharmacological dose, 10−7 M of DHT,
was the minimal dose enabling amplification of BMP-induced signaling in C2C12 cells and that dose
was selected for the following study. As shown in Figure 1, DHT alone (100 nM) had no effect on
mRNA levels of these osteoblastic markers. It was found that DHT treatment (100 nM) significantly
increased BMP-2 (100 ng/mL)-induced ALP mRNA levels, whereas BMP-2-induced expression of
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Figure 1. Effects f androgen on BMP-induced osteoblast marker expression. C2C 2 cells
(2 × 105 cells/ ll) wer treated with the indicated concentrations of DHT, GH, and BMP-2 in
serum-free DMEM. After 48-h cultur , total cellular RNA was extracted and mRNA levels of Runx2,
ALP, osteocalcin, osterix, collagen-1, and Id-1 were examined by real-time RT-PCR. The expression
levels of target genes were standardized by RPL19 mRNA levels in each sample. Results in all panels
are shown as means ± SEM of data from at least three separate experiments, each performed with
triplicate samples. The results were analyzed by ANOVA. For each result within a panel, the values
with different superscript letters are significantly different at p < 0.05.
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We next investigated the combined effects of androgen and GH on BMP-2-induced expression of
osteoblast differentiation markers (Figure 2). The concentration of GH was selected on the basis of
lower but stable concentrations that can induce endogenous IGF-I expression. It has been reported
that stimulation of IGF-I mRNA expression occurs at doses of GH higher than 7.5 ng/mL [23] and
that GH at a concentration of about 10 ng/mL can activate the key intracellular signaling protein Stat5
in C2C12 cells [24]. As shown in Figure 2A, treatment with GH increased mRNA expression of ALP
and osteocalcin induced by BMP-2 (100 ng/mL) in C2C12 cells. Furthermore combined treatment
with DHT (100 nM) and GH (10 ng/mL) significantly increased mRNA expression of Runx2, ALP, and
osteocalcin induced by BMP-2 (100 ng/mL) in C2C12 cells (Figure 2A). In contrast, the BMP-2-induced
mRNA levels of osterix and collagen-1 were not significantly altered by co-treatment with DHT and
GH. In the case of MC3T3-E1 cells, co-treatment with DHT (100 nM) and GH (10 ng/mL) did not
affect the mRNA expression of Runx2, ALP, osteocalcin, or osterix induced by BMP-2 (100 ng/mL)
(Figure 2B). In addition, collagen-1 mRNA was not significantly induced by BMP-2 in MC3T3-E1
cells. Thus it was found that combined treatment with androgen and GH enabled enhancement of










Figure 2. Combined effects of androgen and GH on BMP-induced osteoblast marker expression.
(A) C2C12 and (B) MC3T3-E1 cells (2 × 105 cells/well) were treated with the indicated concentrations of
DHT, GH, and BMP-2 in a serum-free medium. After 48-h culture, total cellular RNA was extracted and
mRNA levels of Id-1 were examined by real-time RT-PCR. The expression levels of target genes were
standardized by RPL19 mRNA levels in each sample. Results in all panels are shown as means ± SEM
of data from at least three separate experiments, each performed with triplicate samples. The results
were analyzed by ANOVA. For each result within a panel, the values with different superscript letters
are significantly different at p < 0.05.
To clarify the combined effects of androgen and GH on BMP-receptor signaling, changes in
Smad1/5/8 phosphorylation and Id-1 mRNA expression were evaluated. As shown in Figure 3A,
stimulation with BMP-2 (100 ng/mL) readily activated Smad1/5/8 phosphorylation in C2C12 cells for
60 min, whereas DHT (100 nM) or GH (100 ng/mL) had no effect on Smad1/5/8 phosphorylation.
It was notable that BMP-2-induced phosphorylation of Smad1/5/8 was significantly enhanced by
combined treatment with DHT and GH for 60 min (Figure 3A), although individual treatment
with DHT or GH was not adequate to enhance BMP-2-induced Smad phosphorylation. A precise
quantification, by measuring BMP target gene Id-1 mRNA levels, showed that treatment with DHT
(100 nM) or GH (10 ng/mL) and, of note, combined treatment with DHT and GH significantly enhanced
the levels of Id-1 mRNA expression induced by BMP-2 treatment (100 ng/mL) for 48 h in C2C12
cells (Figure 3B, upper panel). In contrast, the enhancing effect of DHT and GH on BMP-induced Id-1
expression was not observed in MC3T3-E1 cells (Figure 3B, lower panel). To confirm the combined
effects of DHT (100 nM) and GH (10 ng/mL) on osteoblastic activity induced by BMP-2 (100 ng/mL),
ALP activity was evaluated in cell lysates extracted from these cells (Figure 3C). In accordance with
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the results for Smad phosphorylation and Id-1 mRNA level, it was shown that combined effects of









results  were  analyzed  by  ANOVA.  For  each  result  within  a  panel,  the  values  with  different 
superscript letters are significantly different at p < 0.05.   




treatment  with  BMP‐2,  DHT,  or  GH  (Figure  4B).  To  determine  the  cellular  responsiveness  to 
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IGF‐I‐induced enhancement of collagen‐1 mRNA was restored in the presence of anti‐IGF‐I IgG 
(Figure  4C),  suggesting  neutralization  of  IGF‐I  activity  by  treatment  with  anti‐IGF‐I  IgG. 
Furthermore blockage of endogenous IGF‐I activity by using either anti‐IGF‐I IgG or normal IgG (1 
μg/mL)  failed  to  suppress  the  effects  of  GH  or  combined  treatment  with  DHT  and  GH  on 
BMP‐2‐induced Runx2 mRNA expression  (Figure 4D),  indicating  that endogenous  IGF‐I was not 
likely  to  be  involved  in  the  direct  enhancement  of  GH  actions  in  the  presence  of  BMP‐2  and 
androgen.   
To  investigate  the  mutual  effects  of  androgen  and  GH  on  BMP‐2‐induced  osteoblast 
differentiation, changes  in  the expression of AR and GHR were examined. As shown  in Figure 5, 
GHR mRNA expression was suppressed by  treatment with BMP‐2  (100 ng/mL), regardless of  the 
presenc  of DHT (100 nM), whereas DHT (100 nM) did not affect GHR expression in either C2C12 




Figure 3. Effects of androgen and GH on BMP-receptor signal activation. (A) C2C12 cells
(1 × 105 cells/well) were precultured in a serum-free condition in the absence or presence of DHT
and GH for 48 h and were then stimulated with BMP-2. After 1-h culture with BMP-2 treatment, cells
were lysed and subjected to SDS-PAGE/immunoblotting (IB) analysis using antibodies that can detect
pSmad1/5/8 and tSmad1. The integrated signal density of each protein band was digitally analyzed,
and the ratios of signal intensities of pSmad/tSmad1 were calculated; (B) C2C12 and MC3T3-E1 cells
(2 × 105 cells/well) were treated with the indicated concentrations of DHT, GH, and BMP-2 in a
serum-free medium. After 48-h culture, total cellular RNA was extracted and mRNA levels of Id-1
were examined by real-time RT-PCR. The expression levels of the target gene were standardized by
RPL19 mRNA levels in each sample; (C) C2C12 and MC3T3-E1 cells (1 × 105 cells/well) were treated
with the indicated concentrations of BMP-2, DHT, and GH in a serum-free medium for 72 h, and then
ALP activity in the cell lysates was determined. Results in all panels are shown as means ± SEM of
data from at least three separate experiments, each performed with triplicate samples. The results were
analyzed by ANOVA. For each result within a panel, the values with different superscript letters are
significantly different at p < 0.05.
Of interest, as shown in Figure 4A, the IGF-I mRNA level was significantly increased by
co-treatment with GH (10 ng/mL) and BMP-2 (100 ng/mL) in C2C12 cells. However the enhancement
of IGF-I mRNA was restored in the presence of DHT (100 nM), suggesting that androgen counteracts
GH action or GHR signaling. In addition, the IGF-IR mRNA level was not significantly affected
by treatment with BMP-2, DHT, or GH (Figure 4B). To determine the cellular responsiveness to
exogenous IGF-I, C2C12 cells were treated with IGF-I. As shown in Figure 4C, treatment with IGF-I
(100 ng/mL) for 48 h resulted in significant increases in mRNA levels of IGF-IR and collagen-1, which
were previously reported in human tissues and rat smooth muscle cells [25,26].
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the  cell  culture  in  combination with  either  normal  or  anti‐IGF‐I  IgG  (1  μg/mL)  in  a  serum‐free 
condition  for 48 h. The expression  levels of Runx2 were determined by real‐time RT‐PCR and  the 
expression  levels  of  Runx2 mRNA were  standardized  by  RPL19 mRNA  levels  in  each  sample. 
Results in all panels are shown as means ± SEM of data from at least three separate experiments, each 
Figure 4. Involvement of IGF-I in osteoblast marker expression induced by BMP-2, androgen, and GH.
(A,B) C2C12 and MC3T3-E1 cells (2 × 105 cells/well) were treated with the indicated concentrations of
DHT, GH, and BMP-2 in a serum-free medium. After 48-h culture, total cellular RNA was extracted
and mRNA levels of IGF-I and IGF-IR were examined by real-time RT-PCR. The expression levels
of target genes were standardized by RPL19 mRNA levels in each sample; (C) After C2C12 cells
(2 × 105 cells/well) had been treated with the indicated concentrations of IGF-I and anti-IGF-I IgG
in a serum-free condition for 48 h, total cellular RNA was extracted and mRNA levels of IGF-IR and
collagen-1 were examined by real-time RT-PCR. The expression levels of target genes were standardized
by RPL19 mRNA levels in each sample; (D) BMP-2, DHT and GH were added to the cell culture in
combination with either normal or anti-IGF-I IgG (1 µg/mL) in a serum-free condition for 48 h.
The expression levels of Runx2 were determined by real-time RT-PCR and the expression levels of
Runx2 mRNA were standardized by RPL19 mRNA levels in each sample. Results in all panels are
shown as means ± SEM of data from at least three separate experiments, each performed with triplicate
samples. The results were analyzed by ANOVA and the unpaired t-test. For each result within a panel,
the values with different superscript letters are significantly different at p < 0.05 (A,B). * p < 0.05 vs.
control group (C). n.s., not significant.
IGF-I-induced enhancement of collagen-1 mRNA was restored in the presence of anti-IGF-I IgG
(Figure 4C), suggesting neutralization of IGF-I activity by treatment with anti-IGF-I IgG. Furthermore
blockage of endogenous IGF-I activity by using either anti-IGF-I IgG or normal IgG (1 µg/mL) failed
to suppress the effects of GH or combined treatment with DHT and GH on BMP-2-induced Runx2
mRNA expression (Figure 4D), indicating that endogenous IGF-I was not likely to be involved in the
direct enhancement of GH actions in the presence of BMP-2 and androgen.
To investigate the mutual effects of androgen and GH on BMP-2-induced osteoblast differentiation,
changes in the expression of AR and GHR were examined. As shown in Figure 5, GHR mRNA
expression was suppressed by treatment with BMP-2 (100 ng/mL), regardless of the presence of DHT
(100 nM), whereas DHT (100 nM) did not affect GHR expression in either C2C12 cells (Figure 5A)
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or MC3T3-E1 cells (Figure 5B). AR mRNA expression was also suppressed by BMP-2 (100 ng/mL)
regardless of the presence of GH (10 ng/mL), while GH (10 ng/mL) did not affect AR expression in
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androgen alone was  less effective  for  the osteoblast marker expression  in C2C12 cells.  It was also 






to  estradiol  [5].  In  the  present  study, we  therefore  utilized DHT,  instead  of  testosterone,  as  an 
androgen in order to assess the pure AR action without estrogen converted from testosterone. GH 
replacement for male cases with GH deficiency has also been reported to  improve BMD [8,27]. In 
animal  studies,  male  mice  lacking  GHR  specifically  in  osteoblasts  had  a  dramatic 
Figure 5. Mutual effects of androgen and GH on BMP-induced osteoblast marker expression. (A) C2C12
and (B) MC3T3-E1 cells (2 × 105 cells/well) were treated with the indicated concentrations of DHT, GH,
and BMP-2 in a serum-free medium. After 48-h culture, total cellular RNA was extracted and mRNA
levels of GHR and AR were examined by real-time RT-PCR. The expression levels of target genes were
standardized by RPL19 mRNA levels in each sample. Results in all panels are shown as means ± SEM
of data from at least three separate experiments, each performed with triplicate samples. The results
were analyzed by ANOVA. For each result within a panel, the values with different superscript letters
are significantly different at p < 0.05.
4. Discussion
In the present study, it was found that combined treatment with androgen and GH significantly
increased the levels of Runx2, ALP, and osteocalcin mRNA induced by BMP-2, although the effect
of androgen alone was less effective for the osteoblast marker expression in C2C12 cells. It was
also revealed that combined treatment with DHT and GH augmented BMP-2-induced activity for
Smad1/5/8 signaling, Id-1 transcription, and ALP activity in C2C12 cells but not in MC3T3-E1 cells,
suggesting the significance of the mutual activity of androgen and the GH/IGF-I axis, predominantly
in the early phase of osteoblastic differentiation (Figure 6).
Replacement of testosterone for male patients with androgen deficiency improves their BMD and
bone architecture [9]. These changes are mediated, at least in part, by conversion of testosterone to
estradiol [5]. In the present study, we therefore utilized DHT, instead of testosterone, as an androgen
in order to assess the pure AR action without estrogen converted from testosterone. GH replacement
for male cases with GH deficiency has also been reported to improve BMD [8,27]. In animal studies,
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male mice lacking GHR specifically in osteoblasts had a dramatic skeletal-feminization phenotype
of the femur, while female mice lacking the specified GHR had a significantly reduced number of
osteoblasts [28]. It has also been shown that testosterone and GH act synergistically to induce protein
synthesis and elicit anabolic effects [29,30], while it has also been reported that combined treatment for
males with hypopituitarism did not improve parameters of the distal tibia more than treatment with
testosterone alone [31]. This discrepancy may imply that androgen aromatization is rather important
for explaining the combined effects. However the mutual effects of androgen and GH on the regulation
of bone metabolism have yet to be fully explored.
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process of osteoblast differentiation (Figure 6). In the present study, combined treatment with DHT 
Figure 6. Interaction of androgen and GH in BMP-induced osteoblast marker expression. Combined
treatment with DHT and GH enhanced BMP-2-induced expression of osteoblast markers. DHT and
GH augmented BMP-2-induced Smad1/5/8 signaling and Id-1 transcription in C2C12 cells. The IGF-I
mRNA level was amplified by GH and BMP-2, and the effect was reversed by DHT. The expression of
AR and GHR was suppressed by BMP-2, suggesting a possible feedback loop.
A lack of apparent additive effects of G on androgen action in a clinical study [31] ight be
associated ith the cellular changes in IGF-I, G R, and AR expression in the process of osteoblast
differentiation. In the present study, the IGF-I R A level as a plified by G treat ent in the
presence of B P-2; ho ever the addition of D T decreased the IGF-I expression induced by G
and B P-2 in C2C12 cells (Figure 6). The expression levels of G R and AR ere also odulated by
co-existing B P-2 action. The R A level of IGF-IR as not significantly altered by G treat ent,
hile it as increased by IGF-I treatment. The neutralization of endogenous IGF-I activity using
an anti-IGF-I antibody failed to suppress the combined effects of DHT and G on B P-2-induced
osteoblastic differentiation, implying that endogenous IGF-I was not potentially involved in the mutual
actions of androgen and GH (Figure 6).
These results seem to be consistent with the changes of skeletal structure shown in IGF-I-deficient
mice [32], in which the bones were smaller than those of wild type. Nevertheless the periosteal bone
formation and trabecular architecture were maintained for size [32], suggesting that IGF-I may not
be substantially required for the formation of developed bone. It is possible that GH and IGF-I have
functionally independent activities depending on the stage of bone growth [33]. The finding that
replacement of GH increases bone formation in IGF-I knockout mice [32] also suggests independent
roles for GH and IGF-I in bone formation.
The roles of the /IGF-I axis of bone gro th in ales and fe ales are still unclear. Regarding
the functional link between GH action and AR, it was revealed that BMP-2 has suppressive effects
on GHR and AR expression in both 2C12 and MC3T3-E1 cells. The suppressive effects of BMP-2
on AR and GHR expression in both cell lines may imply the existence of a feedback property in the
J. Clin. Med. 2017, 6, 6 11 of 13
process of osteoblast differentiation (Figure 6). In the present study, combined treatment with DHT
and GH facilitated BMP-2-induced osteoblast marker expression by upregulating the Smad1/5/8
or Id-1 signaling pathways in C2C12 cells, though the mutual interfering effects of androgen, GH,
and BMP-2 should also be considered in this situation. In this regard, Klover et al. [34] reported the
importance of the transcription factor STAT5a/b in skeletal muscle. Using muscle-specific STAT5-null
mice and C2C12 cells, they demonstrated that the expression of AR is regulated by GH action through
STAT5 signaling. On the other hand, IGF-I mRNA induction by co-treatment with GH and BMP-2
was abolished by treatment with DHT in our experiments, implying that androgen also counteracts
GH action or GHR signaling. The suppressor of cytokine signaling 2, as a mediator of crosstalk
between androgen and GH, might be functionally involved in this mechanism [35]. Venken et al. also
showed that DHT administration in GHR-null and orchidectomized male rats restored bone modeling,
suggesting that DHT has an independent effect on bone metabolism [36]. Further study is needed
to clarify the mutual regulation among the activities of AR, GHR, IGF-IR, and IGF binding proteins
(IGFBPs) in the process of osteoblast differentiation in various growth stages.
Collectively the results of this study showed that combined treatment with androgen and
GH enabled enhancement of osteoblast marker expression induced by BMP-2 at the early phase,
as demonstrated in C2C12 cells compared with MC3T3-E1 cells (Figure 6). BMP-2 also elicited
regulatory effects on androgen and GH activities and androgen impaired IGF-I expression induced by
GH and BMP-2. These findings suggested that the combined activities of androgen and GH have roles
in facilitating BMP-2-induced osteoblast differentiation by upregulating Smad signaling but, inversely,
the antagonistic and/or feedback activities of androgen and GH come into existence (Figure 6). Taken
together, this mutual regulation of androgen and GH/IGF-I signaling might be functionally linked to
the process of osteoblastic differentiation shown in the clinical setting of the combined replacement of
androgen and GH.
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